Jing Liu

Prof. Jing Liu


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
YLYang Liu
Yang Liu
LYLi-Meng Yan
Li-Meng Yan
LWLagen Wan
Lagen Wan
TXTian-Xin Xiang
Tian-Xin Xiang
ALAiping Le
Aiping Le
WZWei Zhang
Wei Zhang

1 April 2020 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
XPXingfei Pan
Xingfei Pan
DCDexiong Chen
Dexiong Chen
YXYong Xia
Yong Xia
XWXinwei Wu
Xinwei Wu
TLTangsheng Li
Tangsheng Li
JLJing Liu
Jing Liu

1 July 2020 in Journal of Infection
Verified
Journal Article
Closed access
ZYZhenwei Yang
Zhenwei Yang
JLJialong Liu
Jialong Liu
YZYunjiao Zhou
Yunjiao Zhou
XZXixian Zhao
Xixian Zhao
QZQiu Zhao
Qiu Zhao
JLJing Liu
Jing Liu

21 May 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
HLHaiou Li
Haiou Li
YZYunjiao Zhou
Yunjiao Zhou
MZMeng Zhang
Meng Zhang
HWHaizhou Wang
Haizhou Wang
QZQiu Zhao
Qiu Zhao
JLJing Liu
Jing Liu
Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lies behind the ongoing outbreak of coronavirus disease 2019 (COVID-19). There is a growing understanding of SARS-CoV-2 in virology, epidemiology, and clinical management strategies. However, no anti-SARS-CoV-2 drug or vaccine has been officially approved due to the absence of adequate evidence. Scientists are racing to develop a treatment for COVID-19. Recent studies have revealed many attractive therapeutic options, even if some of them remain to be further confirmed in rigorous preclinical models and clinical trials.

24 June 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
HLHaiou Li
Haiou Li
YZYunjiao Zhou
Yunjiao Zhou
HWHaizhou Wang
Haizhou Wang
MZMeng Zhang
Meng Zhang
PQPeishan Qiu
Peishan Qiu
JLJing Liu
Jing Liu
Nonalcoholic steatohepatitis (NASH), the advanced stage of nonalcoholic fatty liver disease (NAFLD), is emerging as a leading cause of progressive liver fibrosis and end-stage liver disease. Liver macrophages, mainly composed of Kupffer cells (KCs) and monocyte-derived macrophages (MoMFs), play a vital role in NASH progression and regression. Recent advances suggest that cell–cell communication is a fundamental feature of hepatic microenvironment. The reprogramming of cell–cell signaling between macrophages and surrounding cells contributes to the pathogenesis of NASH. In this review, we summarize the current knowledge of NASH regarding the composition of liver macrophages and their communication with surrounding cells, which are composed of hepatocytes, hepatic stellate cells (HSCs), liver sinusoidal endothelial cells (LSECs) and other immune cells. We also discuss the potential therapeutic strategies based on the level of macrophages.

30 July 2020 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
PQPeishan Qiu
Peishan Qiu
YZYunjiao Zhou
Yunjiao Zhou
FWFan Wang
Fan Wang
HWHaizhou Wang
Haizhou Wang
MZMeng Zhang
Meng Zhang
JLJing Liu
Jing Liu
Background At present, novel coronavirus disease 2019 (COVID-19) has become a serious global public health problem. The current meta-analysis aimed to find risk factors for the COVID-19-related death, helping to enhance the efficacy and reduce the mortality of COVID-19. Methods We searched PubMed, Embase, medRxiv, and Cochrane Library for articles published between January 1, 2020, and April 13, 2020. We statistically analyzed the risk factors of the COVID-19 deceased with meta-analysis. Results A total of 2401 patients in 15 articles were included in this study. Meta-analysis showed that 66.6% of COVID-19 deceased were male, with a median age of 69.9 years. Common symptoms of deceased included fever (70.6–100%), dyspnea (38.89–85.7%), cough (22.4–78%), and fatigue (22–61.9%). The incidence of hypertension, chronic cardiovascular disease, diabetes, and chronic cerebrovascular disease among the COVID-19 deceased were 38.56% (95% confidence interval (CI) 25.84 ~ 52.12%), 17.54% (95% CI 13.38 ~ 21.69%), 22.2% (95% CI 19.30 ~ 25.10%), and 15.58% (95% CI 10.05 ~ 21.12%), respectively. Compared with the surviving COVID-19 patients, the deceased had lower platelet levels (mean difference (MD) = − 39.35, 95% CI − 55.78 ~ − 22.93) and higher C-reactive protein (CRP) (MD = 80.85, 95% CI 62.53 ~ 99.18) and lactate dehydrogenase (LDH) (MD = 246.65, 95% CI 157.43 ~ 335.88) at admission. The most common complications of the deceased were acute respiratory distress syndrome (ARDS) (OR = 100.36, 95% CI 64.44 ~ 156.32) and shock (OR = 96.60, 95% CI 23.80 ~ 392.14). Conclusion Most of the COVID-19 deceased were elderly males. Fever, dyspnea, dry cough, fatigue, hypertension, chronic cardiovascular and cerebrovascular disease, diabetes, and laboratory examinations showed low levels of platelet content, increased CRP and LDH were associated with the risk of dying. ARDS and shock were risk factors for death in COVID-19 patients.